Notably, future studies should also assess animal body weight, liver fibrosis scores, and standard blood markers of MASLD in our current mouse models, as well as determine whether ALDH2 inhibition or genetic ablation in hepatocyte‐specific cGas knockout mice can reverse HFD‐induced MASLD. Here, CGAS is linked to metabolic dysfunction-associated steatotic liver disease.